Pharmaceutical company Novo Nordisk (the sponsor) has advised us that it will gradually discontinue some of its earlier generation insulin products over the next 2 years.
The sponsor has announced that:
- in some cases, although one presentation of a product is discontinued, the product will remain available in a different presentation (for example, the FlexTouch prefilled pen may be replaced by a Penfill cartridge)
- patients will have ample time to move to alternative options before products are discontinued
- this is part of a global strategy and is not related to product safety, quality or effectiveness.
The products that we anticipate will be affected are listed in the table below:
| Product presentation | Anticipated date of discontinuation |
|---|---|
| Mixtard 30 Penfill (insulin human/isophane (NPH) insulin human 30/70) | October 2024 |
| Fiasp vials (fast acting insulin aspart) | December 2024 |
| Ryzodeg FlexTouch (insulin degludec + insulin aspart 70/30) | February 2025 (go to our webpage for information) |
| Protaphane InnoLet (isophane (NPH) insulin human) | February 2025 |
| Fiasp FlexTouch (fast acting insulin aspart) | June 2025 |
| Protaphane Penfill (isophane (NPH) insulin human) | December 2026 |
| Levemir FlexPen & Penfill (insulin detemir) | December 2026 |
| Actrapid Penfill (human insulin) | December 2026 |
| NovoFine Autocover | December 2026 |
We will inform patients and health care professionals about any changes in the availability of individual insulin products through alerts and updates to this page.
Updated information will also be available in the Medicine Shortage Reports Database ─ search by the active ingredient ‘Insulin’ and filter by the ‘Discontinuations’ tab on the database homepage.
We recognise the vital role of insulin for people with diabetes in Australia. We will work with the sponsor to minimise the impact of these discontinuations by providing early advice that includes alternative options.